Payload Information
General Information of This Payload
| Payload ID | PAY0ZWDQO |
|||||
|---|---|---|---|---|---|---|
| Name | 9106-IM-2 |
|||||
| Synonyms |
9106-IM-2
Click to Show/Hide
|
|||||
| Target(s) | DNA topoisomerase 1 (TOP1) | |||||
| Structure |
|
|||||
| Formula | C30H31FN4O6 |
|||||
| Isosmiles | CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2c-1nc1cc(F)c(C)c3c1c2[C@@H](NC(=O)[C@H](OCN)C1CC1)CC3 |
|||||
| InChI |
InChI=1S/C30H31FN4O6/c1-3-30(39)18-8-22-25-16(10-35(22)28(37)17(18)11-40-29(30)38)24-20(34-27(36)26(41-12-32)14-4-5-14)7-6-15-13(2)19(31)9-21(33-25)23(15)24/h8-9,14,20,26,39H,3-7,10-12,32H2,1-2H3,(H,34,36)/t20-,26+,30-/m0/s1
|
|||||
| InChIKey |
UGTGLDLIIGUWBO-AQDMSIBGSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
562.598 |
Polar area |
145.77 |
||
Complexity |
562.2227629 |
xlogp Value |
2.34202 |
|||
Heavy Count |
41 |
Rot Bonds |
6 |
|||
Hbond acc |
9 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
SHR-A2102 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05735275 | Phase Status | Phase 1 | ||
| Clinical Description |
Safety, tolerability, pharmacokinetics, and efficacy of SHR-A2102, in subjects with locally advanced or metastatic solid tumor malignancies: a phase 1 open-label, one-arm, multicenter study.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05701709 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, single-arm, multi-center phase 1 clinical study to evaluate the safety, tolerability, efficacy and pharmacokinetics of SHR-A2102 in patients with advanced solid tumors.
|
||||
SHR-A2009 [Phase 3]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [3] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05394818 | Phase Status | Phase 1 | ||
| Clinical Description |
An open-label, phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [4] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT05114759 | Phase Status | Phase 1 | ||
| Clinical Description |
A phase 1, open-label, multicenter clinical study to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-A2009 for injection in patients with advanced solid tumors.
|
||||
References